137 related articles for article (PubMed ID: 8027371)
1. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas.
Matias-Guiu X; Cuatrecasas M; Musulen E; Prat J
J Clin Pathol; 1994 Apr; 47(4):337-9. PubMed ID: 8027371
[TBL] [Abstract][Full Text] [Related]
2. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
3. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
4. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.
Nakamura T; Yana I; Kobayashi T; Shin E; Karakawa K; Fujita S; Miya A; Mori T; Nishisho I; Takai S
Jpn J Cancer Res; 1992 Dec; 83(12):1293-8. PubMed ID: 1483945
[TBL] [Abstract][Full Text] [Related]
8. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
9. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
10. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
11. Mutations of p53 in thyroid carcinoma with an insular component.
Takeuchi Y; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Thyroid; 1999 Apr; 9(4):377-81. PubMed ID: 10319944
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
13. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression.
Moore D; Ohene-Fianko D; Garcia B; Chakrabarti S
Histopathology; 1998 Jan; 32(1):35-42. PubMed ID: 9522214
[TBL] [Abstract][Full Text] [Related]
15. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas.
Kim YW; Do IG; Park YK
Pathol Res Pract; 2006; 202(11):759-65. PubMed ID: 17029809
[TBL] [Abstract][Full Text] [Related]
16. Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53.
Wyllie FS; Haughton MF; Rowson JM; Wynford-Thomas D
Br J Cancer; 1999 Mar; 79(7-8):1111-20. PubMed ID: 10098744
[TBL] [Abstract][Full Text] [Related]
17. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers.
Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P
Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205
[TBL] [Abstract][Full Text] [Related]
18. Proliferating cell nuclear antigen expression in papillary thyroid carcinoma.
Ando H; Funahashi H; Ito M; Imai T; Takagi H
J Clin Pathol; 1996 Aug; 49(8):657-9. PubMed ID: 8881917
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of genes encoding mitochondrial proteins in papillary thyroid carcinomas.
Haugen DR; Fluge Ø; Reigstad LJ; Varhaug JE; Lillehaug JR
Thyroid; 2003 Jul; 13(7):613-20. PubMed ID: 12964965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
